Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001628098-25-000010
Filing Date
2025-12-17
Accepted
2025-12-17 20:07:46
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 22912
2 JOINT FILING AGREEMENT ex-99-12182025_011243.htm EX-99.1 50279
3 TRANSACTIONS IN COMMON STOCK DURING THE PAST SIXTY DAYS ex-99-12182025_011244.htm EX-99.2 45758
  Complete submission text file 0001628098-25-000010.txt   120821
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

EIN.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472
Business Address 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472 (617) 674-9274
Disc Medicine, Inc. (Subject) CIK: 0001816736 (see all company filings)

EIN.: 851612845 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91633 | Film No.: 251581003
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)